Epidemiological trends and financial outcomes in radical prostatectomy among medicare beneficiaries, 1991 to 1993

Journal of Urology

Volumn 160, Issue 2, 1998, Pages 445-448

  Litwin, Mark S ^a   Pasta, David J ^a   Stoddard, Marcia L ^a   Henning, James M ^a   Carroll, Peter R ^a  

^a NONE

Author keywords

Medicare; Prostatectomy; Prostatic neoplasms; United States Health Care Financing Administration

Indexed keywords

ANDROGEN; GONADORELIN AGONIST;

ADJUVANT THERAPY; AGE; AGED; ARTICLE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE FINANCING; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; MEDICARE; ORCHIECTOMY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RACE DIFFERENCE; UNITED STATES;

EID: 0032323357     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62921-5     Document Type: Article

References (20)

1. Benoit, R. M. and Naslund, M. J.: The economics of prostate cancer screening. Oncology, 11: 1533, 1997.
2. Litwin, M. S., Kahn, K. L. and Reccius, N.: Why do sicker patients cost more? A charge-based analysis of patients undergoing prostatectomy. J. Urol., 149: 84, 1993.
3. Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J., Petros, J. A. and Andriole, G. L.: Measurement of serum prostate-specific antigen in serum as a screening test for prostate cancer. New Engl. J. Med., 324: 1156, 1991.
4. Boring, C. C., Squires, T. S. and Tong, T.: Cancer statistics, 1992. CA, 42: 19, 1992.
5. Boring, C. C., Squires, T. S. and Tong, T.: Cancer statistics, 1993. CA, 43: 7, 1993.
6. Harlan, L., Brawley, O., Pommerenke, F., Wali, P. and Kramer, B.: Geographic, age, and racial variation in the treatment of local/ regional carcinoma of the prostate. J. Clin. Oncol., 13: 93, 1995.
7. Lu-Yao, G. L. and Greenberg, E. R.: Changes in prostate cancer incidence and treatment in USA. Lancet, 343: 251, 1994.
8. Lu-Yao, G. L., McLerran, D., Wasson, J., Wennberg, J. E. and the Prostate Patient Outcomes Research Team: An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. J.A.M.A., 269: 2633, 1993.
9. Dayal, H. H., Polissar, L. and Dahlberg, S.: Race, socioeconomic status, and other prognostic factors for survival from prostate cancer. J. Natl. Cancer Inst., 74: 1001, 1985.
10. Litwin, M. S. and Breslow, L.: Decreased racial differences in the incidence and mortality of prostate cancer: a phenomenon of increasing age. J. Urol., part 2, 147: 469A, Abstract 1025, 1992.
11. Lu-Yao, G. L., Friedman, M. and Yao, S. L.: Use of radical prostatectomy among Medicare beneficiaries before and after the introduction of prostate specific antigen testing. J. Urol., 157: 2219, 1997.
12. Wennberg, J. and Gittelsohn, A.: Variations in medical care among small areas. Sci. Amer., 246: 120, 1982.
13. Wennberg, J. E., Freeman, J. L. and Culp, W. J.: Are hospital services rationed in New Haven or over-utilised in Boston? Lancet, 1: 1185, 1987.
14. Catalona, W. J. and Bigg, S. W.: Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J. Urol., 143: 538, 1990.
15. Litwin, M. S., Sacher, S. J., Cohen, W. S.: The Resource-Based Relative Value Scale: methods, results and impacts on urology. J. Urol., 150: 981, 1993.
16. Kahn, K. L., Rubenstein, L. V., Draper, D., Kosecoff, J., Rogers, W. H., Keeler, E. B. and Brook, R. H.: The effects of the DRG-based prospective payment system on quality of care for hospitalized Medicare patients. J.A.M.A., 264: 1953, 1990.
17. Petros, J. A. and Catalona, W. J.: Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer. J. Urol., 147: 1574, 1992.
18. Parra, R. O., Isorna, S., Perez, M. G., Cummings, J. M. and Boullier, J. A.: Radical perineal prostatectomy without pelvic lymphadenectomy: selection criteria and early results. J. Urol., 155: 612, 1996.
19. Höltl, W. and Albrecht, W.: Re: eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J. Urol., 155: 296, 1996.
20. Soloway, M. S., Sharifi, R., Wajsman, Z., McLeod, D., Wood, D. P. Jr., Puras-Baez, A. and The Lupron Depot Neoadjuvant Prostate Cancer Study Group: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J. Urol., 154: 424, 1995.